drugset / Trial / NCT01767103

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers

NCT01767103

Phase 4 Completed 21 enrolled ApoPharma
Non-randomizedParallel-groupOpen-label

Summary

Multi-center, non-randomized, open-label, single-dose, parallel group study to determine the effect of impaired hepatic function on the PK of deferiprone and its 3-O-glucuronide metabolite following a single oral dose of 33mg/kg Ferriprox®.

Timeline

Start
2013-01
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferiprone Small molecule 33 mg/kg Oral

Indications

No indication recorded.